XML 46 R37.htm IDEA: XBRL DOCUMENT
v3.24.0.1

Segment Data - Revenues by Geographic Areas (Detail) - USD ($) $ in Millions | 3 Months Ended
--- | ---
Dec. 31, 2023 | Dec. 31, 2022
Segment Reporting Information [Line Items] |  |
Revenues | $ 4,706 | $ 4,586
Operating Segments | Medical |  |
Segment Reporting Information [Line Items] |  |
Revenues | 2,230 | 2,154
Operating Segments | Life Sciences |  |
Segment Reporting Information [Line Items] |  |
Revenues | 1,288 | 1,302
Operating Segments | Interventional |  |
Segment Reporting Information [Line Items] |  |
Revenues | 1,188 | 1,129
United States |  |
Segment Reporting Information [Line Items] |  |
Revenues | 2,749 | 2,730
United States | Operating Segments | Medical |  |
Segment Reporting Information [Line Items] |  |
Revenues | 1,360 | 1,303
United States | Operating Segments | Life Sciences |  |
Segment Reporting Information [Line Items] |  |
Revenues | 587 | 645
United States | Operating Segments | Interventional |  |
Segment Reporting Information [Line Items] |  |
Revenues | 802 | 782
International |  |
Segment Reporting Information [Line Items] |  |
Revenues | 1,957 | 1,856
International | Operating Segments | Medical |  |
Segment Reporting Information [Line Items] |  |
Revenues | 870 | 852
International | Operating Segments | Life Sciences |  |
Segment Reporting Information [Line Items] |  |
Revenues | 701 | 657
International | Operating Segments | Interventional |  |
Segment Reporting Information [Line Items] |  |
Revenues | 386 | 347
Medication Delivery Solutions | Operating Segments | Medical |  |
Segment Reporting Information [Line Items] |  |
Revenues | 1,052 | 1,039
Medication Delivery Solutions | United States | Operating Segments | Medical |  |
Segment Reporting Information [Line Items] |  |
Revenues | 639 | 620
Medication Delivery Solutions | International | Operating Segments | Medical |  |
Segment Reporting Information [Line Items] |  |
Revenues | 413 | 419
Medication Management Solutions | Operating Segments | Medical |  |
Segment Reporting Information [Line Items] |  |
Revenues | 747 | 706
Medication Management Solutions | United States | Operating Segments | Medical |  |
Segment Reporting Information [Line Items] |  |
Revenues | 594 | 564
Medication Management Solutions | International | Operating Segments | Medical |  |
Segment Reporting Information [Line Items] |  |
Revenues | 153 | 142
Pharmaceutical Systems | Operating Segments | Medical |  |
Segment Reporting Information [Line Items] |  |
Revenues | 431 | 409
Pharmaceutical Systems | United States | Operating Segments | Medical |  |
Segment Reporting Information [Line Items] |  |
Revenues | 127 | 119
Pharmaceutical Systems | International | Operating Segments | Medical |  |
Segment Reporting Information [Line Items] |  |
Revenues | 304 | 290
Integrated Diagnostic Solutions | Operating Segments | Life Sciences |  |
Segment Reporting Information [Line Items] |  |
Revenues | 913 | 952
Integrated Diagnostic Solutions | United States | Operating Segments | Life Sciences |  |
Segment Reporting Information [Line Items] |  |
Revenues | 444 | 508
Integrated Diagnostic Solutions | International | Operating Segments | Life Sciences |  |
Segment Reporting Information [Line Items] |  |
Revenues | 470 | 445
Biosciences | Operating Segments | Life Sciences |  |
Segment Reporting Information [Line Items] |  |
Revenues | 375 | 349
Biosciences | United States | Operating Segments | Life Sciences |  |
Segment Reporting Information [Line Items] |  |
Revenues | 143 | 137
Biosciences | International | Operating Segments | Life Sciences |  |
Segment Reporting Information [Line Items] |  |
Revenues | 232 | 212
Surgery | Operating Segments | Interventional |  |
Segment Reporting Information [Line Items] |  |
Revenues | 369 | 363
Surgery | United States | Operating Segments | Interventional |  |
Segment Reporting Information [Line Items] |  |
Revenues | 280 | 287
Surgery | International | Operating Segments | Interventional |  |
Segment Reporting Information [Line Items] |  |
Revenues | 88 | 76
Peripheral Intervention | Operating Segments | Interventional |  |
Segment Reporting Information [Line Items] |  |
Revenues | 454 | 433
Peripheral Intervention | United States | Operating Segments | Interventional |  |
Segment Reporting Information [Line Items] |  |
Revenues | 234 | 236
Peripheral Intervention | International | Operating Segments | Interventional |  |
Segment Reporting Information [Line Items] |  |
Revenues | 220 | 197
Urology and Critical Care | Operating Segments | Interventional |  |
Segment Reporting Information [Line Items] |  |
Revenues | 365 | 333
Urology and Critical Care | United States | Operating Segments | Interventional |  |
Segment Reporting Information [Line Items] |  |
Revenues | 287 | 259
Urology and Critical Care | International | Operating Segments | Interventional |  |
Segment Reporting Information [Line Items] |  |
Revenues | $ 78 | $ 74

X
- Definition Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss). + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(1)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30 Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42 Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22 Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32 Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40 Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22 Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32 Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41 Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 235 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-05(b)(2)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1 + Details
Name: | us-gaap_Revenues
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_SegmentReportingInformationLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=bdx_MedicalMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=bdx_LifeSciencesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=bdx_InterventionalMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementGeographicalAxis=country_US
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementGeographicalAxis=us-gaap_NonUsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | bdx_OrganizationalUnitAxis=bdx_MedicationDeliverySolutionsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | bdx_OrganizationalUnitAxis=bdx_MedicationManagementSolutionsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | bdx_OrganizationalUnitAxis=bdx_PharmaceuticalSystemsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | bdx_OrganizationalUnitAxis=bdx_IntegratedDiagnosticSolutionsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | bdx_OrganizationalUnitAxis=bdx_BiosciencesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | bdx_OrganizationalUnitAxis=bdx_SurgeryMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | bdx_OrganizationalUnitAxis=bdx_PeripheralInterventionMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | bdx_OrganizationalUnitAxis=bdx_UrologyandCriticalCareMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |